{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T17:44:08Z","timestamp":1793295848291,"version":"4.5.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,13]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>PANTHER is a global, randomized phase 3 trial of pevonedistat+azacitidine (n = 227) vs azacitidine monotherapy (n = 227) in patients with newly diagnosed higher-risk myelodysplastic syndromes (MDS; n = 324), higher-risk chronic myelomonocytic leukemia (n = 27), or acute myeloid leukemia (AML) with 20% to 30% blasts (n = 103). The primary end point was event-free survival (EFS). In the intent-to-treat population, the median EFS was 17.7 months with pevonedistat+azacitidine vs 15.7 months with azacitidine (hazard ratio [HR], 0.968; 95% confidence interval [CI], 0.757-1.238; P = .557) and in the higher-risk MDS cohort, median EFS was 19.2 vs 15.6 months (HR, 0.887; 95% CI, 0.659-1.193; P = .431). Median overall survival (OS) in the higher-risk MDS cohort was 21.6 vs 17.5 months (HR, 0.785; P = .092), and in patients with AML with 20% to 30% blasts was 14.5 vs 14.7 months (HR, 1.107; P = .664). In a post hoc analysis, median OS in the higher-risk MDS cohort for patients receiving &amp;gt;3 cycles was 23.8 vs 20.6 months (P\u00a0=\u00a0.021) and for &amp;gt;6 cycles was 27.1 vs 22.5 months (P = .008). No new safety signals were identified, and the azacitidine dose intensity was maintained. Common hematologic grade \u22653 treatment emergent adverse events were anemia (33% vs 34%), neutropenia (31% vs 33%), and thrombocytopenia (30% vs 30%). These results underscore the importance of large, randomized controlled trials in these heterogeneous myeloid diseases and the value of continuing therapy for &amp;gt;3 cycles. The trial was registered on clinicaltrials.gov as #NCT03268954.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007334","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T20:22:47Z","timestamp":1655842967000},"page":"5132-5145","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":135,"title":["Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS\/chronic myelomonocytic leukemia or low-blast-percentage AML"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-8766","authenticated-orcid":false,"given":"Lionel","family":"Ad\u00e8s","sequence":"first","affiliation":[{"name":"1INSERM U944, Assistance Publique-H\u00f4pitaux de Paris (AP-HP), H\u00f4pital Saint Louis and University of Paris, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0559-9556","authenticated-orcid":false,"given":"Larisa","family":"Girshova","sequence":"additional","affiliation":[{"name":"2Federal Almazov North-West Medical Research Centre, Saint-Petersburg, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim A.","family":"Doronin","sequence":"additional","affiliation":[{"name":"3City Clinical Hospital 40, Moscow, Russia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1467-6779","authenticated-orcid":false,"given":"Mar\u00eda","family":"D\u00edez-Campelo","sequence":"additional","affiliation":[{"name":"4Institute for Biomedical Research of Salamanca (IBSAL), University Hospital of Salamanca, Salamanca, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Valc\u00e1rcel","sequence":"additional","affiliation":[{"name":"5Hematology Department, Vall Hebron Institute of Oncology (VHIO), Vall d'Hebron, University Hospital, Barcelona, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[{"name":"6Sarah Cannon at Research Medical Center, Kansas City, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora-Athina","family":"Viniou","sequence":"additional","affiliation":[{"name":"7Hematology Unit, First, Department of Internal Medicine, Laikon General Hospital, National and Kapodistrian University of Athens, Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariusz","family":"Woszczyk","sequence":"additional","affiliation":[{"name":"8University of Opole, Provincial Hospital, Opole, Poland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"De Paz Arias","sequence":"additional","affiliation":[{"name":"9Hematology, Hospital Universitario La Paz-IDIPaz, Madrid, Spain;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-3473","authenticated-orcid":false,"given":"Argiris","family":"Symeonidis","sequence":"additional","affiliation":[{"name":"10Hematology Division, Department of Internal Medicine, University Hospital Patras, Patras, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4384-9031","authenticated-orcid":false,"given":"Achilles","family":"Anagnostopoulos","sequence":"additional","affiliation":[{"name":"11Hematology Department, General Hospital \u201cGeorge Papanikolaou,\u201d Thessaloniki, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo Ciliao","family":"Munhoz","sequence":"additional","affiliation":[{"name":"12Hematology and Oncology Clinic, Erasto Gaertner Hospital, Curitiba, Brazil;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1863-3239","authenticated-orcid":false,"given":"Uwe","family":"Platzbecker","sequence":"additional","affiliation":[{"name":"13Department of Hematology and Cellular Therapy, Leipzig University Hospital, Leipzig, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5439-2172","authenticated-orcid":false,"given":"Valeria","family":"Santini","sequence":"additional","affiliation":[{"name":"14MDS (Myelodysplastic Syndrome) Unit, Hematology, Azienda Ospedaliero-Universitaria (AOU) Careggi, University of Florence, Florence, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fram","sequence":"additional","affiliation":[{"name":"15Takeda Development Center Americas, Inc (TDCA), Lexington, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Yuan","sequence":"additional","affiliation":[{"name":"15Takeda Development Center Americas, Inc (TDCA), Lexington, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Friedlander","sequence":"additional","affiliation":[{"name":"15Takeda Development Center Americas, Inc (TDCA), Lexington, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas V.","family":"Faller","sequence":"additional","affiliation":[{"name":"15Takeda Development Center Americas, Inc (TDCA), Lexington, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkael A.","family":"Sekeres","sequence":"additional","affiliation":[{"name":"16Division of Hematology, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"2022090215234130400_B1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/HS9.0000000000000101","article-title":"Epidemiology and impact of preceding or underlying disease in secondary acute myeloid leukemia","volume":"2","author":"Granfeldt \u00d8stg\u00e5rd","year":"2018","journal-title":"HemaSphere."},{"issue":"10","key":"2022090215234130400_B2","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood."},{"key":"2022090215234130400_B3","doi-asserted-by":"crossref","first-page":"683401","DOI":"10.3389\/fimmu.2021.683401","article-title":"Inflammatory pathophysiology as a contributor to myeloproliferative neoplasms","volume":"12","author":"Fisher","year":"2021","journal-title":"Front Immunol."},{"issue":"11","key":"2022090215234130400_B4","first-page":"1399","article-title":"Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management","volume":"95","author":"Garcia-Manero","year":"2020","journal-title":"Am\u00a0J\u00a0Hematol."},{"key":"2022090215234130400_B5","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.5045\/br.2021.2020321","article-title":"Diagnosis and treatment of chronic myelomonocytic leukemia","volume":"56","author":"Kwon","year":"2021","journal-title":"Blood Res."},{"issue":"1","key":"2022090215234130400_B6","doi-asserted-by":"crossref","first-page":"60","DOI":"10.6004\/jnccn.2017.0007","article-title":"Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Greenberg","year":"2017","journal-title":"J\u00a0Natl\u00a0Compr Canc Netw."},{"issue":"41","key":"2022090215234130400_B7","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1200\/EDBK_320113","article-title":"Navigating myelodysplastic and myelodysplastic\/myeloproliferative overlap syndromes","volume":"41","author":"Hasserjian","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2022090215234130400_B8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.canep.2016.03.011","article-title":"Myeloid malignancies in the real-world: occurrence, progression and survival in the UK\u2019s population-based Haematological Malignancy Research Network 2004-15","volume":"42","author":"Roman","year":"2016","journal-title":"Cancer Epidemiol."},{"key":"2022090215234130400_B9","author":"Howlader","year":"2020"},{"issue":"6","key":"2022090215234130400_B10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.blre.2005.01.004","article-title":"Myelodysplasic syndromes: a comprehensive review","volume":"19","author":"Catenacci","year":"2005","journal-title":"Blood Rev."},{"key":"2022090215234130400_B11","doi-asserted-by":"crossref","first-page":"106339","DOI":"10.1016\/j.leukres.2020.106339","article-title":"Advances in non-intensive chemotherapy treatment options for adults diagnosed with acute myeloid leukemia","volume":"91","author":"Griffiths","year":"2020","journal-title":"Leuk Res."},{"issue":"7","key":"2022090215234130400_B12","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.3390\/cancers13071610","article-title":"Risk-adapted, individualized treatment strategies of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML)","volume":"13","author":"Bewersdorf","year":"2021","journal-title":"Cancers (Basel)."},{"issue":"2","key":"2022090215234130400_B13","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/bjh.17746","article-title":"Updates on targeted therapies for acute myeloid leukaemia","volume":"196","author":"Kayser","year":"2022","journal-title":"Br J Haematol."},{"key":"2022090215234130400_B14","doi-asserted-by":"crossref","first-page":"106555","DOI":"10.1016\/j.leukres.2021.106555","article-title":"A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival","volume":"104","author":"Garcia","year":"2021","journal-title":"Leuk Res."},{"issue":"1","key":"2022090215234130400_B15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428194.2018.1464155","article-title":"Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care","volume":"60","author":"Bell","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"5","key":"2022090215234130400_B16","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/bjh.14305","article-title":"Comparative clinical effectiveness of azacitidine versus decitabine in older patients with myelodysplastic syndromes","volume":"175","author":"Zeidan","year":"2016","journal-title":"Br J Haematol."},{"issue":"9","key":"2022090215234130400_B17","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/leu.2015.115","article-title":"Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry","volume":"29","author":"Bernal","year":"2015","journal-title":"Leukemia."},{"issue":"7239","key":"2022090215234130400_B18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nature07884","article-title":"An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer","volume":"458","author":"Soucy","year":"2009","journal-title":"Nature."},{"issue":"1","key":"2022090215234130400_B19","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.molcel.2009.12.024","article-title":"Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ","volume":"37","author":"Brownell","year":"2010","journal-title":"Mol Cell."},{"issue":"7","key":"2022090215234130400_B20","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1177\/1947601910382898","article-title":"The NEDD8 conjugation pathway and its relevance in cancer biology and therapy","volume":"1","author":"Soucy","year":"2010","journal-title":"Genes Cancer."},{"issue":"18","key":"2022090215234130400_B21","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1182\/blood-2009-11-254862","article-title":"Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia","volume":"115","author":"Swords","year":"2010","journal-title":"Blood."},{"key":"2022090215234130400_B22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cellsig.2018.01.009","article-title":"Protein neddylation and its alterations in human cancers for targeted therapy","volume":"44","author":"Zhou","year":"2018","journal-title":"Cell Signal."},{"issue":"7","key":"2022090215234130400_B23","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1038\/s41375-021-01125-4","article-title":"Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS\/CMML or low-blast AML","volume":"35","author":"Sekeres","year":"2021","journal-title":"Leukemia."},{"issue":"7","key":"2022090215234130400_B24","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood."},{"issue":"12","key":"2022090215234130400_B25","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood."},{"issue":"2","key":"2022090215234130400_B26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood."},{"issue":"24","key":"2022090215234130400_B27","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","article-title":"Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol."},{"issue":"24","key":"2022090215234130400_B28","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American intergroup study SWOG S1117","volume":"35","author":"Sekeres","year":"2017","journal-title":"J Clin Oncol."},{"issue":"12","key":"2022090215234130400_B29","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1038\/leu.2017.159","article-title":"A phase 1b\/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with \u2a7d30% blasts","volume":"31","author":"Garcia-Manero","year":"2017","journal-title":"Leukemia."},{"key":"2022090215234130400_B30","author":"Celgene Corporation","year":"2004"},{"issue":"3","key":"2022090215234130400_B31","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol."},{"issue":"6","key":"2022090215234130400_B32","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.30533","article-title":"Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes","volume":"123","author":"Garcia-Manero","year":"2017","journal-title":"Cancer."},{"key":"2022090215234130400_B33","author":"Sallman","year":"2020"},{"key":"2022090215234130400_B34","volume-title":"European Hematology Association (EHA)","author":"Wei","year":"2021"},{"key":"2022090215234130400_B35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood-2020-139492","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study. [abstract]","volume":"136","author":"Garcia","year":"2020","journal-title":"Blood."},{"issue":"14","key":"2022090215234130400_B36","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.20.02341","article-title":"Eprenetapopt (APR-246) and azacitidine in TP53-mutant myelodysplastic syndromes","volume":"39","author":"Sallman","year":"2021","journal-title":"J Clin Oncol."},{"key":"2022090215234130400_B37","author":"Aprea Therapeutics","year":"2020"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/5132\/1918258\/advancesadv2022007334.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/17\/5132\/1918258\/advancesadv2022007334.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T15:24:25Z","timestamp":1662132265000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/17\/5132\/485649\/Pevonedistat-plus-azacitidine-vs-azacitidine-alone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":37,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022,9,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007334","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]}}}